A Study of Tetanus Antibody of Healthy Adults

NCT07724379 | Completed

• 2 other identifiers: 2024R5242024IR10
• Study Type: observational
• Target: 2,009
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to learn about antibody level of tetanus of adults in high-income city of china. The main question it aims to answer is:

1. 1.Analysis of tetanus antibody distribution across different age groups
2. 2.Evaluation of the TQS method for determining antibody status
3. 3.Correlation between primary vaccination history and tetanus antibody concentrations Blood samples were voluntarily provided by adult healthy participants for tetanus antibody analysis over a continuous collection period of more than one year.

Conditions

Tetanus

Keywords

Healthy Adults; Vaccination; Protective Efficacy; Observational Study; TQS; tetanus

Outcome Measures

Primary Outcomes (1)

• Tetanus Antibody Level

  Single blood draw

  Baseline (single blood draw at enrollment)

Secondary Outcomes (1)

• tetanus antibody level by TQS/mTQS method

  Baseline (single blood draw at enrollment)

Study Arms (5)

age group

20-29;30-39;40-49;50-59;≥60

gender group

male; female

education background

high school; bachelor; master; et al

primary vaccination

≥3 doses TTCV; \< 3 doses TTCV; unknown

last TTCV dose duration

≤5 year;5-10 year; \>10 year; unkown

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study will enroll healthy adults aged 18 years who reside in Beijing. Participants will be recruited voluntarily from the general population. Both males and females are eligible. Participants must be willing to provide a blood sample and complete a brief questionnaire regarding their vaccination history. Individuals with recent tetanus vaccination (within 5 years), acute illness, pregnancy, or immunosuppressive conditions will be excluded.

You may qualify if:

• Voluntarily sign the informed consent form；
• Be aged 18 years or older；
• Be willing to provide a blood sample for biochemical testing

You may not qualify if:

• Receipt of immunoglobulin, blood, or blood products within 6 months prior to enrollment；
• Refusal to provide tetanus vaccination history (including vaccination records, CDC vaccine administration registry, or subject's recall)；
• Individuals with recent tetanus vaccination (within 5 years), acute illness, pregnancy, or immunosuppressive conditions will be excluded

Sponsors & Collaborators

• Peking University First Hospital: lead

Study Sites (1)

Peking University First Hospital

Beijing, Beijing Municipality, 100034, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

blood

MeSH Terms

Conditions

Tetanus

Condition Hierarchy (Ancestors)

Clostridium Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Target Duration: 6 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief Physician， Department Director

Study Record Dates

• First Submitted: July 1, 2026
• First Posted: July 24, 2026
• Study Start: May 4, 2025
• Primary Completion: March 3, 2026
• Study Completion: May 15, 2026
• Last Updated: July 24, 2026

Record last verified: 2026-07

Locations

CN (1)